Difference between revisions of "Craig Thompson"
(unstub) |
|||
Line 4: | Line 4: | ||
|nationality=US | |nationality=US | ||
|image=Craig Thompson.jpg | |image=Craig Thompson.jpg | ||
+ | |description=President of [[Memorial Sloan Kettering Cancer Center]] and board member of [[Big Pharma]] [[Merck]] who attended the [[2013 Bilderberg meeting]], where one of the subjects was "Major Trends in Medical Research" | ||
|interests=cancer | |interests=cancer | ||
+ | |spouses=Tullia Lindsten | ||
|birth_date=1953 | |birth_date=1953 | ||
|birth_place= | |birth_place= | ||
Line 10: | Line 12: | ||
|death_place= | |death_place= | ||
|constitutes=biologist | |constitutes=biologist | ||
− | |sourcewatch= | + | |alma_mater=University of Pennsylvania Medical School,Harvard Medical School,Fred Hutchinson Cancer Research Center |
+ | |sourcewatch= | ||
|employment= | |employment= | ||
− | }}'''Craig B. Thompson''' | + | }}'''Craig B. Thompson''' is an American [[cell biologist]] who was president of the research institution [[Memorial Sloan Kettering Cancer Center]] 2010-2022.<ref>http://www.mskcc.org/magazine/october-2010/craig-thompson-named-president-msk</ref> He attended the [[2013 Bilderberg meeting]], where one of the subjects was "Major Trends in Medical Research", presumably either lobbying for [[Big Pharma]] (having an interests in [[Merck]]), or for some [[deep state agenda]] under a medical pretext. |
+ | |||
+ | ==Education== | ||
+ | Thompson received his bachelor's degree from [[Dartmouth College]] and went on to get his medical degree in 1977 from the [[University of Pennsylvania Medical School]]. He received clinical training in internal medicine at [[Harvard Medical School]] and in medical oncology at the [[Fred Hutchinson Cancer Research Center]] at the University of Washington. | ||
+ | |||
+ | ==Career== | ||
+ | After completing his training, Thompson became a physician at the [[National Naval Medical Center]] in [[Bethesda, Maryland]]<ref>https://www.jci.org/articles/view/82626</ref>, and an assistant professor of medicine at the [[Uniformed Services University of the Health Sciences]]. In 1987, he joined the faculty of the [[University of Michigan]] as an assistant professor of medicine and an assistant investigator in the Howard Hughes Medical Institute. From 1993 until he joined the [[University of Pennsylvania]], he was affiliated with the [[University of Chicago]], where he was professor of medicine, a Howard Hughes investigator, and director of the Gwen Knapp Center for Lupus and Immunology Research. | ||
+ | |||
+ | Thompson joined the University of Pennsylvania in 1999 as a professor of medicine, the scientific director of The Leonard and Madlyn Abramson Family Cancer Research Institute, and the first chairman of the Department of Cancer Biology. In 2006 he was named director of the [[Abramson Cancer Center]] of the University of Pennsylvania and associate vice president for cancer services of the University of Pennsylvania Health System.<ref>https://www.propublica.org/article/memorial-sloan-kettering-chief-executive-resigns-from-mercks-board-of-directors</ref> | ||
+ | |||
+ | Thompson became president and chief executive officer of [[Memorial Sloan Kettering Cancer Center]] in November 2010.<ref>http://www.mskcc.org/magazine/october-2010/craig-thompson-named-president-msk</ref> | ||
+ | |||
+ | ===Resigning from Merck=== | ||
+ | In [[2018]], Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, said that he would resign his seats on the boards of drugmaker [[Merck]] and another public company, "the latest fallout from a widening institutional reckoning over relationships between cancer center leaders and for-profit health care companies". Thompson has served on the board of Merck, the maker of the blockbuster cancer drug Keytruda, since [[2008]].<ref>https://www.propublica.org/article/memorial-sloan-kettering-chief-executive-resigns-from-mercks-board-of-directors</ref><ref>https://www.biopharmadive.com/news/memorial-sloan-kettering-scandal-raises-questions-for-pharmas-biggest-corp/540750/</ref> | ||
+ | |||
+ | ==Covid== | ||
+ | In December 2020, the Memorial Sloan Kettering (MSK) rolled up their sleeves to receive the [[COVID-19 vaccine]]. "We are encouraged by the demonstrated safety and efficacy of the [[Pfizer vaccine]], as well as the [[Moderna vaccine]], which is expected to be approved by the [[FDA]] soon," said Craig B. Thompson, MD, president and CEO of MSK. "The Pfizer vaccine was approved after successful large-scale trials with more than 43,000 volunteer participants, rigorous peer review by independent scientists, and adherence to FDA regulatory standards."<ref>https://www.mskcc.org/news/msk-healthcare-heroes-roll-their-sleeves-receive-covid-19-vaccine</ref> | ||
+ | |||
+ | He interviewed [[Rochelle Walensky]] at the [[Economic Club of New York]] in April 2022.<ref>https://www.econclubny.org/documents/10184/109144/2022WalenskyTranscript.pdf</ref> | ||
+ | |||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
− |
Latest revision as of 05:55, 12 December 2024
Craig Thompson (biologist) | |
---|---|
Born | 1953 |
Nationality | US |
Alma mater | University of Pennsylvania Medical School, Harvard Medical School, Fred Hutchinson Cancer Research Center |
Spouse | Tullia Lindsten |
Interests | cancer |
President of Memorial Sloan Kettering Cancer Center and board member of Big Pharma Merck who attended the 2013 Bilderberg meeting, where one of the subjects was "Major Trends in Medical Research" |
Craig B. Thompson is an American cell biologist who was president of the research institution Memorial Sloan Kettering Cancer Center 2010-2022.[1] He attended the 2013 Bilderberg meeting, where one of the subjects was "Major Trends in Medical Research", presumably either lobbying for Big Pharma (having an interests in Merck), or for some deep state agenda under a medical pretext.
Education
Thompson received his bachelor's degree from Dartmouth College and went on to get his medical degree in 1977 from the University of Pennsylvania Medical School. He received clinical training in internal medicine at Harvard Medical School and in medical oncology at the Fred Hutchinson Cancer Research Center at the University of Washington.
Career
After completing his training, Thompson became a physician at the National Naval Medical Center in Bethesda, Maryland[2], and an assistant professor of medicine at the Uniformed Services University of the Health Sciences. In 1987, he joined the faculty of the University of Michigan as an assistant professor of medicine and an assistant investigator in the Howard Hughes Medical Institute. From 1993 until he joined the University of Pennsylvania, he was affiliated with the University of Chicago, where he was professor of medicine, a Howard Hughes investigator, and director of the Gwen Knapp Center for Lupus and Immunology Research.
Thompson joined the University of Pennsylvania in 1999 as a professor of medicine, the scientific director of The Leonard and Madlyn Abramson Family Cancer Research Institute, and the first chairman of the Department of Cancer Biology. In 2006 he was named director of the Abramson Cancer Center of the University of Pennsylvania and associate vice president for cancer services of the University of Pennsylvania Health System.[3]
Thompson became president and chief executive officer of Memorial Sloan Kettering Cancer Center in November 2010.[4]
Resigning from Merck
In 2018, Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, said that he would resign his seats on the boards of drugmaker Merck and another public company, "the latest fallout from a widening institutional reckoning over relationships between cancer center leaders and for-profit health care companies". Thompson has served on the board of Merck, the maker of the blockbuster cancer drug Keytruda, since 2008.[5][6]
Covid
In December 2020, the Memorial Sloan Kettering (MSK) rolled up their sleeves to receive the COVID-19 vaccine. "We are encouraged by the demonstrated safety and efficacy of the Pfizer vaccine, as well as the Moderna vaccine, which is expected to be approved by the FDA soon," said Craig B. Thompson, MD, president and CEO of MSK. "The Pfizer vaccine was approved after successful large-scale trials with more than 43,000 volunteer participants, rigorous peer review by independent scientists, and adherence to FDA regulatory standards."[7]
He interviewed Rochelle Walensky at the Economic Club of New York in April 2022.[8]
Event Participated in
Event | Start | End | Location(s) | Description |
---|---|---|---|---|
Bilderberg/2013 | 6 June 2013 | 9 June 2013 | Watford UK | The 2013 Bilderberg group meeting. |
References
- ↑ http://www.mskcc.org/magazine/october-2010/craig-thompson-named-president-msk
- ↑ https://www.jci.org/articles/view/82626
- ↑ https://www.propublica.org/article/memorial-sloan-kettering-chief-executive-resigns-from-mercks-board-of-directors
- ↑ http://www.mskcc.org/magazine/october-2010/craig-thompson-named-president-msk
- ↑ https://www.propublica.org/article/memorial-sloan-kettering-chief-executive-resigns-from-mercks-board-of-directors
- ↑ https://www.biopharmadive.com/news/memorial-sloan-kettering-scandal-raises-questions-for-pharmas-biggest-corp/540750/
- ↑ https://www.mskcc.org/news/msk-healthcare-heroes-roll-their-sleeves-receive-covid-19-vaccine
- ↑ https://www.econclubny.org/documents/10184/109144/2022WalenskyTranscript.pdf